UPC CFI 233/2023
Jul 7, 2023·EP3797685 · SYSTEMS AND METHODS FOR DISPLAY DEVICE AND SENSOR ELECTRONICS UNIT COMMUNICATION
Action number: ACT 547520/2023
- Case details
- StatusCase Closed (No infringement)ActionInfringementCategoryMain infringement action
- Parties
- Claimants
- Dexcom Inc.Operating co.
Representatives- Marcus Grosch-Quinn Emanuel Urquhart & Sullivan LLP
- Alexander Esslinger-Betten & Resch Partnerschaftsgesellschaft mbB
- Not named-Quinn Emanuel Urquhart & Sullivan LLP
Respondents- Abbott LaboratoriesOperating co.
- Abbott Diabetes Care Inc.Operating co.
- Abbott GmbHOperating co.
- Abbott Diagnostics GmbHOperating co.
- Abbott Logistics B.V.Operating co.
- Abbott (S.A./N.V.)Operating co.
- Abbott s.r.l.Operating co.
- Abbott B.V.Operating co.
- Abbott Scandinavia AktiebolagOperating co.
- Abbott FranceOperating co.
Representatives- Wim Maas-Taylor Wessing
- Division
- Munich LD
- Technology
- Electrical engineeringDigital communication
- InstrumentsMedical technology
- Language
- English
- First decided
- Jul 31, 2024
| Infringement found | Median days to first decision | |
|---|---|---|
| All UPC | 53% (62/117) | 124 |
| Munich LD | Locked | Locked |
| Judge Matthias Zigann | Locked | Locked |
| Judge Tobias Pichlmaier | Locked | Locked |
| Judge Tatyana Zhilova | Locked | Locked |
| Judge Alain Dumont | Locked | Locked |
At the UPC: Dexcom Group (39 cases)·Abbott Group (67 cases)
This dispute contains 6 other proceedings
UPC CoA 569/2024·UPC APP 49196/2024·UPC APP 45331/2024·CC 586829/2023·CC 586960/2023 and 1 more
- —revocation counterclaim
Summary: 1. EP 3 797 685 B1 is entirely revoked with effect in the territories of the Contracting Member States for which the European Patent had effect at the time of the counterclaim for revocation, namely [17 states]. 2. The auxiliary requests are dismissed. ... 4. All infringement claims are dismissed.
| Document title | Date | Public |
|---|---|---|
| workflow closed | 2025-07-22 | Public |
| workflow closed | 2025-07-22 | Not public |
| workflow closed | 2025-07-22 | Public |
| workflow closed | 2025-07-22 | Not public |
| workflow closed | 2025-07-22 | Public |
| workflow closed | 2025-07-22 | Not public |
| Outcome of the Order | 2025-04-17 | Not public |
| workflow closed | 2025-04-17 | Public |
| Consent | 2025-01-16 | Not public |
| Comment on withdrawal | 2025-01-14 | Not public |
DexCom Inc. brought an infringement action against multiple Abbott entities before the Munich Local Division concerning EP 3 797 685 (a CGM system patent). Abbott counterclaimed for revocation and succeeded: the court found the patent invalid for lack of novelty/inventive step both as granted and in DexCom's two auxiliary request forms, and revoked it entirely. DexCom's failure to advance specific arguments distinguishing the dependent claims was noted as a further reason those claims fell. All infringement claims were dismissed and DexCom was ordered to bear all costs.
Patent EP 3 797 685 invalid as granted and in all auxiliary request forms
RespondentLegal basis: Art. 138(1) EPC; Art. 65(2) UPCANote: Munich LD upheld Abbott's counterclaim for revocation, finding the CGM patent invalid for lack of novelty/inventive step in all claim versions.
Dependent claims are invalid for same reasons as claim 1 where claimant provides no specific arguments distinguishing dependent claims
RespondentLegal basis: Art. 138(1) EPCNote: Claimant merely asserted dependent claims contain claim 1 features and are novel/inventive for the same reasons; no specific arguments advanced; court held dependent claims also invalid.
EP 3 797 685 as granted is valid
ClaimantLegal basis: Art. 54/56 EPCReason: Patent found invalid for lack of novelty/inventive step as granted.
Auxiliary requests 1 and 2 are valid
ClaimantLegal basis: Art. 54/56 EPCReason: Both auxiliary requests also found invalid; dismissed.
Browse other cases on this principle.